跳至主要内容
临床试验/ACTRN12612001175864
ACTRN12612001175864已完成未知

A study involving early breast cancer patients upon completion of active treatment to determine their views on a pilot breast cancer survivorship care plan designed for a New Zealand context.

Regional Cancer Treatment Service, MidCentral Health DHB0 个研究点目标入组 30 人开始时间: 2012年11月6日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Educational / counselling / training
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1.Females or males with histologically diagnosed early breast cancer who have undergone surgery alone or just completed adjuvant chemotherapy and/or radiation therapy if this is required. Patients can be receiving adjuvant hormone therapy or adjuvant herceptin therapy.
  • 2.Age >=18 yrs.
  • 3.Able to read English proficiently.
  • 4.Willing and able to comply with all study requirements.
  • 5.Signed, written informed consent.

排除标准

  • 1.Patients who do not have a histological breast cancer diagnosis.
  • 2.Patients with metastatic breast cancer.
  • 3.Patients still receiving adjuvant chemotherapy or radiation therapy.
  • 4.Life expectancy of less than 6 months.
  • 5.Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse.

研究者

发起方
Regional Cancer Treatment Service, MidCentral Health DHB

相似试验

进行中(未招募)
1 期
Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta®Breast Cancer
EUCTR2012-002039-28-ESSandoz GmbH308
已完成
3 期
A study to evaluate the Efficacy and Safety of LA-EP2006 and Neulasta® in patients with breast cancer.
CTRI/2012/10/003065Sandoz GmbH302
招募中
不适用
A study to estimate improvement in quality of life, cost effectiveness of radiotherapy in patients of breast cancer with bone metastases.
CTRI/2018/03/012317Tata Memorial Hospital
招募中
2 期
Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO (BELLINI trial)breast cancer
NL-OMON54814ederlands Kanker Instituut90
进行中(未招募)
1 期
Pre-operative study for breast cancer with nivolumab in combination with other therapyMedDRA version: 21.1Level: LLTClassification code 10006188Term: Breast cancer female NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10006194Term: Breast cancer NOS stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10006195Term: Breast cancer NOS stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10006196Term: Breast cancer NOS stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-004188-30-NLKI-AV90